Ticagrelor: A safe option as part of triple therapy?
Keyword(s):
Patients with atrial fibrillation who have concurrent coronary artery disease requiring percutaneous coronary intervention are subsequently prescribed dual antiplatelet therapy and anticoagulation resulting in triple therapy (TT). Ticagrelor, a reversibly binding P2Y12 antiplatelet agent, has shown superiority to clopidogrel in prevention of ischemic events and death, but is also associated with a small increase in the incidence of intracranial bleeding. This bleeding risk may be enhanced in the setting of TT. The objective of this report is to describe a case of a 70-year-old male prescribed TT with ticagrelor and to review the current literature on the safety of ticagrelor as a part of TT.
2021 ◽
Vol 77
(18)
◽
pp. 1036
2018 ◽
Vol 52
(9)
◽
pp. 884-897
◽
2015 ◽
Vol 65
(10)
◽
pp. A1815
2018 ◽
Vol 71
(11)
◽
pp. A1027